The New York-headquartered firm, which recently decided to focus on gene therapy, has to decide whether to partner Zimura or go it alone.
Shares in Iveric Bio are continuing to soar after the small US biotech said its lead asset Zimura slowed eyesight deterioration in patients with dry age-related macular degeneration (AMD).
Top-line data from a Phase IIb trial of Zimura (avacincaptad pegol) showed that the complement C5 inhibitor reduced the rate...
The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.
Wales-based group launches with $140m series A.
CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.
